Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

MERCK & CO., INC.

(MRK)
  Report
Delayed Nyse  -  04:03 2022-11-28 pm EST
108.45 USD   +0.88%
11/22Merck & Co.'s Keytruda Combo Extends Survival in Late-stage Stomach Cancer Study
MT
11/22Merck to Acquire Imago BioSciences Inc
AQ
11/22Merck's Keytruda Meets Primary Endpoint in Phase 3 Trial of Keytruda in Gastric Cancer Patients
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Days
:
Hours
:
Minutes
:
Seconds

Merck & Co.'s Keytruda Wins Four New Approvals in Japan for Cancer Indications

09/27/2022 | 10:22am EST


ę MT Newswires 2022
All news about MERCK & CO., INC.
11/22Merck & Co.'s Keytruda Combo Extends Survival in Late-stage Stomach Cancer Study
MT
11/22Merck to Acquire Imago BioSciences Inc
AQ
11/22Merck's Keytruda Meets Primary Endpoint in Phase 3 Trial of Keytruda in Gastric Cancer ..
MT
11/22Merck's Keytruda Hits Main Endpoint in Stomach Cancer Study
DJ
11/22Merck Announces Phase 3 KEYNOTE-859 Trial Met Primary Endpoint of Overall Survival in P..
BU
11/22Merck Announces Phase 3 Keynote-859 Trial Met Primary Endpoint of Overall Survival in P..
CI
11/21Merck & Co. To Buy Bone Marrow Disease-focused Imago BioSciences For $1.4 Billion
MT
11/21Sector Update: Health Care Stocks Advance Modestly
MT
11/21Trending : Merck to Acquire Imago BioSciences for $1.35 Billion
DJ
11/21Sector Update: Health Care Stocks Staying on Positive Ground
MT
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
Financials (USD)
Sales 2022 59 072 M - -
Net income 2022 14 812 M - -
Net Debt 2022 18 689 M - -
P/E ratio 2022 18,6x
Yield 2022 2,57%
Capitalization 275 B 275 B -
EV / Sales 2022 4,97x
EV / Sales 2023 4,91x
Nbr of Employees 67 500
Free-Float 70,8%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 108,45 $
Average target price 109,61 $
Spread / Average Target 1,07%
EPS Revisions
Managers and Directors
Robert M. Davis President, Chief Executive Officer & Director
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Kenneth C. Frazier Executive Chairman
Dave Williams EVP, Chief Information & Digital Officer
Lisa LeCointe-Cephas Chief Ethics & Compliance Officer, SVP
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.41.51%274 964
JOHNSON & JOHNSON3.66%463 626
ELI LILLY AND COMPANY32.23%347 547
ABBVIE INC.17.01%280 085
PFIZER, INC.-16.05%278 252
ROCHE HOLDING AG-17.59%271 275